Adaptive and Acquired Resistance to EGFR Inhibitors Converge on the MAPK Pathway.
about
Pharmacodynamic endpoints as clinical trial objectives to answer important questions in oncology drug development.ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma.Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase.Increased expression of miR-641 contributes to erlotinib resistance in non-small-cell lung cancer cells by targeting NF1.
P2860
Adaptive and Acquired Resistance to EGFR Inhibitors Converge on the MAPK Pathway.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Adaptive and Acquired Resistance to EGFR Inhibitors Converge on the MAPK Pathway.
@en
type
label
Adaptive and Acquired Resistance to EGFR Inhibitors Converge on the MAPK Pathway.
@en
prefLabel
Adaptive and Acquired Resistance to EGFR Inhibitors Converge on the MAPK Pathway.
@en
P2093
P2860
P356
P1433
P1476
Adaptive and Acquired Resistance to EGFR Inhibitors Converge on the MAPK Pathway.
@en
P2093
Jian-Xin Gao
Mengzhao Wang
Minjiang Chen
Pengfei Ma
Xiaojing Zhao
P2860
P304
P356
10.7150/THNO.14409
P577
2016-05-24T00:00:00Z